The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) held the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.
Chimeric Antigen Receptor T-cell therapy (CAR-T) is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases. The recent approvals of the first CAR T Cell treatments in Europe provide a great opportunity to fight hematologic malignancies, but also poses serious challenges given the peculiar nature of the treatment. Continue reading
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax for the investigational treatment of multiple myeloma. Continue reading
Myeloma Patients Europe (MPE) is participating in the Horizon 2020 project, MMPredict, aimed at developing a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients.
The MMpredict consortium has reached a new milestone in this project by completing the recruitment of the patient samples required in this project. With more than 800 myeloma samples recruited, the project team meets its aimed target population. The current efforts will now be focused on completing the genetic analysis of the obtained study material. During this stage, tumour heterogeneity (i.e. the differences between people’s myeloma) and the patient’s intrinsic characteristics will be investigated. Continue reading
Second cohort of the ADP trainees during ESMO 2018.
Patient input into medical research is becoming increasingly important. The MPE Advocate Development Programme aims to help myeloma and AL amyloidosis advocates understand the research and development process of drugs, from the preclinical stages through to post-marketing surveillance and national access. Topics include clinical trial design, regulation, pricing and health technology assessment (HTA). The programme combines a series of theoretical sessions delivered by experts with practical sessions that take place during the most important myeloma scientific meetings in Europe such as the European Haematology Association (EHA) Annual Meeting or the European Society of Medical Oncology (ESMO) Annual Meeting. Continue reading
Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2018. Continue reading
The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019. Continue reading
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2018. Continue reading
Myeloma Patients Europe (MPE) is participating in the Horizon 2020 project, MMPredict, aimed to develop a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients. To explain the main goals of MMPredict, MPE filmed a video with some partners working in the project consortium. Now this video, recorded in English, has been translated into four additional languages: German, Spanish, Dutch and Italian. Continue reading
Data from the phase III MAIA clinical trial was presented yesterday as part of the Late-Breaking Abstracts Session during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego. Continue reading
Initial data from the ongoing phase I clinical trial of bb21217 (CRB-402) were presented at the 60th Annual Meeting of the American Society of Hematology (ASH). This is an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory myeloma. Continue reading